Genetic polymorphisms and non-small-cell lung cancer: future paradigms Polimorfismos genéticos e carcinoma de pulmão de células não pequenas: os paradigmas do futuro
作者： Ramon Andrade , Bezerra de Mello
DOI:
关键词:
摘要: ABSTRACT This article addresses some current issues about genetic polymorphisms studied in the non-small-cell lung cancer translational field. Furthermore, it discusses new potential biomarkers regarding risk and prognosis. Keywords: Lung neoplasms; Polymorphism, genetic; Tumor makers, biological; Prognosis RESUMO O presente artigo faz uma abordagem de questoes atuais sobre os polimorfismos geneticos, que tem sido objeto estudo translacional no contexto do carcinoma pulmao celulas nao pequenas. Alem disso, discute novos potenciais biomarcadores risco e prognostico. Descritores: Neoplasias pulmao; Polimorfismo genetico; Marcadores biologicos tumor; Prognostico INTRODUCTION Currently, non-small cell (NSCLC) is a neoplasm of worldwide importance due to its high incidence mortality. (1) Patients stage IV according TNM Classification Malignant Tumors, American Joint Cancer Committee (AJCC), (2) have median overall survival (OS) 10 11 months after treatments.
参考文章(26)
Peter Goldstraw, John Crowley, Kari Chansky, Dorothy J Giroux, Patti A Groome, Ramon Rami-Porta, Pieter E Postmus, Valerie Rusch, Leslie Sobin, International Association for the Study of Lung Cancer International Staging Committee, None, The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of Thoracic Oncology. ,vol. 2, pp. 706- 714 ,(2007) , 10.1097/JTO.0B013E31812F3C1A
Ramon Andrade de Mello, Dânia Sofia Marques, Rui Medeiros, António MF Araújo, None, Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies World journal of clinical oncology. ,vol. 2, pp. 367- 376 ,(2011) , 10.5306/WJCO.V2.I11.367
Eunice L. Kwak, Yung-Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai-Hong I. Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella-Garcia, Woo-Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, WeiWei Tan, Leena Gandhi, Mari Mino-Kenudson, Greg C. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate, Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 363, pp. 1693- 1703 ,(2010) , 10.1056/NEJMOA1006448
Ramon Andrade de Mello, Bruno M Costa, Rui M Reis, Venceslau Hespanhol, None, Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies Recent Patents on Anti-cancer Drug Discovery. ,vol. 7, pp. 118- 131 ,(2012) , 10.2174/157489212798357994
M Reck, J Von Pawel, P von Zatloukal, R Ramlau, V Gorbounova, V Hirsh, N Leighl, J Mezger, V Archer, N Moore, C Manegold, BO17704 Study Group, Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Annals of Oncology. ,vol. 21, pp. 1804- 1809 ,(2010) , 10.1093/ANNONC/MDQ020
Rebecca Suk Heist, Rihong Zhai, Geoffrey Liu, Wei Zhou, Xihong Lin, Li Su, Kofi Asomaning, Thomas J. Lynch, John C. Wain, David C. Christiani, VEGF Polymorphisms and Survival in Early-Stage Non-Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 26, pp. 856- 862 ,(2008) , 10.1200/JCO.2007.13.5947
, Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer The New England Journal of Medicine. ,vol. 368, pp. 1980- 1991 ,(2013) , 10.1056/NEJMOA1209120
M Taron, R Rosell, M Santarpia, E Felip, N Reguart, F Cecere, M Cuello, Usefulness of predictive tests for cancer treatment Bulletin Du Cancer. ,vol. 93, pp. 10101- 10108 ,(2006)
Siwen Hu-Lieskovan, Daniel Vallbohmer, Wu Zhang, Dongyun Yang, Alexander Pohl, Melissa J. Labonte, Peter P. Grimminger, Arnulf H. Hölscher, Robert Semrau, Dirk Arnold, Kathrin Dellas, Annelies Debucquoy, Karin Haustermans, Jean-Pascal H. Machiels, Christine Sempoux, Claus Rödel, Matej Bracko, Vaneja Velenik, Heinz-Josef Lenz, EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clinical Cancer Research. ,vol. 17, pp. 5161- 5169 ,(2011) , 10.1158/1078-0432.CCR-10-2666
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim, Ravi Salgia, Panagiotis Fidias, Jeffrey A Engelman, Leena Gandhi, Pasi A Jänne, Daniel B Costa, Geoffrey I Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith Wilner, Jeffrey W Clark, Alice T Shaw, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncology. ,vol. 13, pp. 1011- 1019 ,(2012) , 10.1016/S1470-2045(12)70344-3